argenx SE (0QW0.L)
| Previous close | 82.30 |
| Open | 107.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 105.00 - 107.10 |
| 52-week range | 105.00 - 107.10 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 4.005B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.65 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
Submission package based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous (SC) efgartigimod compared to intravenously administered VYVGART® (efgartigimod alfa-fcab) based on total immunoglobulin G (IgG) reduction at day 29 Amsterdam, the Netherlands – September 21, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the submission
- Globe Newswire
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
Scientific presentations demonstrate argenx’s leadership in FcRn blockade and commitment to innovating for patients across multiple neuromuscular diseases Additional data from ADAPT+ open-label study support long-term safety of VYVGART® (efgartigimod alfa-fcab) for treatment of adult patients with generalized myasthenia gravis (gMG), who experienced consistent improvements in function and strength over multiple years Pooled data from ADAPT studies and real-world clinical setting suggest VYVGART
- Globe Newswire
argenx Appoints Camilla Sylvest to Board of Directors
September 8, 2022 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical orga
